Nicotine + Placebo

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Smoking Cessation

Conditions

Smoking Cessation

Trial Timeline

Mar 1, 2009 → Jun 1, 2010

About Nicotine + Placebo

Nicotine + Placebo is a pre-clinical stage product being developed by Johnson & Johnson for Smoking Cessation. The current trial status is completed. This product is registered under clinical trial identifier NCT00882375. Target conditions include Smoking Cessation.

What happened to similar drugs?

17 of 20 similar drugs in Smoking Cessation were approved

Approved (17) Terminated (0) Active (3)

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00882375Pre-clinicalCompleted

Competing Products

20 competing products in Smoking Cessation

See all competitors
ProductCompanyStageHype Score
Brenipatide + PlaceboEli LillyPhase 2
42
Nicotine + Nicotine + NicotineJohnson & JohnsonPhase 2
35
Nicotine replacement therapy + Nicotine replacement therapyJohnson & JohnsonPhase 2
35
Nicotine Patch + Placebo PatchJohnson & JohnsonPhase 1
29
Nicotine Patch + Placebo Patch + SLS Comparator PatchJohnson & JohnsonPhase 1
29
Nicotine Patch + Nicotine Patch Comparator + Placebo PatchJohnson & JohnsonPhase 1
29
Nicotine Patch + Placebo Patch + No Patch ControlJohnson & JohnsonPhase 1
29
Nicotine gum + Placebo gum + Nicotine inhaler + Placebo inhalerJohnson & JohnsonPhase 3
40
Nicotine patch, nicotine inhaler, bupropion + Nicotine patchJohnson & JohnsonApproved
43
AZD4041 + PlaceboAstraZenecaPhase 1
29
taranabantMerckPhase 2
35
Nicotine replacement therapyNovartisPre-clinical
22
AFQ065NovartisPhase 1
29
Liraglutide + PlaceboNovo NordiskPhase 2
35
VareniclinePfizerPhase 2
35
placebo + Varenicline TartaratePfizerPhase 3
40
varenicline + placeboPfizerApproved
39
varenicline (CP-526,555)PfizerPhase 3
40
placebo + vareniclinePfizerApproved
43
Varenicline + BupropionPfizerPhase 3
40